CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company is headquartered in Sunnyvale, California.
| Revenue (TTM) | $108.72M |
| Gross Profit (TTM) | $97.04M |
| EBITDA | $-74.85M |
| Operating Margin | -70.00% |
| Return on Equity | -52.50% |
| Return on Assets | -26.70% |
| Revenue/Share (TTM) | $2.87 |
| Book Value | $3.03 |
| Price-to-Book | 8.58 |
| Price-to-Sales (TTM) | 9.50 |
| EV/Revenue | 8.4 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 29.90% |
| Shares Outstanding | $38.84M |
| Float | $26.86M |
| % Insiders | 11.70% |
| % Institutions | 87.92% |
Volatility is currently contracting
SUNNYVALE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the third quarter ended September 30, 2026.
SUNNYVALE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the commercial launch of its delirium monitoring solution on its point-of-care brain monitoring platform.
SUNNYVALE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York City. The fireside chat will take place on Wednesday, November 11, 2026, at 7:00 a.m. Pacific Standard Time / 10:00 a.m. Eastern Standard Time.
SUNNYVALE, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the third quarter of 2026 after the close of trading on Tuesday, November 3, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 3, 2026.
CeriBell NASDAQ: CBLL outlined its plans to expand its brainwave-monitoring platform beyond seizure detection, pointing to new products for delirium, pediatric patients and eventually stroke as it continues to build its hospital customer base.
CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript
Although the revenue and EPS for CeriBell, Inc. (CBLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind Dual Seizure and Delirium Monitoring Platform Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind Dual Seizure and Delirium Monitoring Platform
SUNNYVALE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointments of Thomas “Tom” West and Sharon O'Keefe to its Board of Directors.
SUNNYVALE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity 46th Annual Growth Conference in Boston. The fireside chat will take place on Wednesday, August 12, 2026, at 6:00 a.m. Pacific Daylight Time / 9:00 a.m. Eastern Daylight Time.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CBLL and any ticker you trade — then tracks every position and per-strategy win rate.
